Dexetimide

Identification

Generic Name
Dexetimide
DrugBank Accession Number
DB08997
Background

A muscarinic antagonist that has been used to treat neuroleptic-induced parkinsonism. Benzetimide is the (-)-enantimorph of dexetimide.

Type
Small Molecule
Groups
Withdrawn
Structure
Thumb
Weight
Average: 362.4647
Monoisotopic: 362.199428086
Chemical Formula
C23H26N2O2
Synonyms
  • Dexetimida
  • Dexetimide
  • Dexetimidum

Pharmacology

Indication

Not Available

Pharmacology
Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Contraindications
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Adverseeffects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
1,2-Benzodiazepine1,2-Benzodiazepine may increase the central nervous system depressant (CNS depressant) activities of Dexetimide.
AcetazolamideAcetazolamide may increase the central nervous system depressant (CNS depressant) activities of Dexetimide.
AcetophenazineAcetophenazine may increase the central nervous system depressant (CNS depressant) activities of Dexetimide.
AclidiniumThe risk or severity of adverse effects can be increased when Dexetimide is combined with Aclidinium.
AdenosineThe risk or severity of Tachycardia can be increased when Adenosine is combined with Dexetimide.
AgomelatineAgomelatine may increase the central nervous system depressant (CNS depressant) activities of Dexetimide.
AlfentanilThe risk or severity of adverse effects can be increased when Dexetimide is combined with Alfentanil.
AlimemazineAlimemazine may increase the central nervous system depressant (CNS depressant) activities of Dexetimide.
AlloinThe therapeutic efficacy of Alloin can be decreased when used in combination with Dexetimide.
AlmotriptanAlmotriptan may increase the central nervous system depressant (CNS depressant) activities of Dexetimide.
Interactions
Identify potential medication risks
Easily compare up to 40 drugs with our drug interaction checker.
Get severity rating, description, and management advice.
Learn more
Food Interactions
Not Available

Products

Products2
Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Product Ingredients
IngredientUNIICASInChI Key
Dexetimide hydrochlorideB987A3XX7D21888-96-0XSOOSXRNMDUWEM-GNAFDRTKSA-N
International/Other Brands
Tremblex

Categories

ATC Codes
N04AA08 — Dexetimide
Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as n-benzylpiperidines. These are heterocyclic Compounds containing a piperidine ring conjugated to a benzyl group through one nitrogen ring atom.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Piperidines
Sub Class
Benzylpiperidines
Direct Parent
N-benzylpiperidines
Alternative Parents
Phenylmethylamines / Benzylamines / Tetrahydropyridines / Aralkylamines / Trialkylamines / N-acylimines / Lactims / Amino acids and derivatives / Propargyl-type 1,3-dipolar organic compounds / Azacyclic compounds
show 4 more
Substituents
Amine / Amino acid or derivatives / Aralkylamine / Aromatic heteromonocyclic compound / Azacycle / Benzenoid / Benzylamine / Carbonyl group / Carboxylic acid derivative / Hydrocarbon derivative
show 17 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
Not Available
Affected organisms
Not Available

Chemical Identifiers

UNII
43477QYX3D
CAS number
21888-98-2
InChI Key
LQQIVYSCPWCSSD-HSZRJFAPSA-N
InChI
InChI=1S/C23H26N2O2/c26-21-11-14-23(22(27)24-21,19-9-5-2-6-10-19)20-12-15-25(16-13-20)17-18-7-3-1-4-8-18/h1-10,20H,11-17H2,(H,24,26,27)/t23-/m1/s1
IUPAC Name
(3S)-1'-benzyl-3-phenyl-[3,4'-bipiperidine]-2,6-dione
SMILES
O=C1CC[C@@](C2CCN(CC3=CC=CC=C3)CC2)(C(=O)N1)C1=CC=CC=C1

References

Synthesis Reference

U.S. Patent 3,125,578.

General References
Not Available
PubChem Compound
30843
PubChem Substance
310264958
ChemSpider
28615
BindingDB
50228206
RxNav
3267
ChEBI
135531
ChEMBL
CHEMBL1908364
ZINC
ZINC000006927490
Wikipedia
Dexetimide

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
Tablet
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)299-301.5U.S. Patent 3,125,578.
Predicted Properties
PropertyValueSource
Water Solubility0.00469 mg/mLALOGPS
logP3.54ALOGPS
logP3.38ChemAxon
logS-4.9ALOGPS
pKa (Strongest Acidic)11.69ChemAxon
pKa (Strongest Basic)8.66ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area49.41 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity106.34 m3·mol-1ChemAxon
Polarizability40.52 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Drug created on June 16, 2014 19:39 / Updated on February 21, 2021 18:52